EUVIMEDEUVIMED entdecken
Open Access

Prognostic factors in adult patients with medulloblastoma

Ytel Garcilazo-Reyes iD, Pierre Dal Col, Franck Bielle iD, Karima Mokhtari, Loïc Feuvret, Julian Jacob, Alberto Duran-Peña, Laurent Capelle, Julien Savatovsky, Franck Bourdeaut iD, Julien Masliah-Planchon iD, Bernardo Cacho-Díaz und 3 weitere

Neuro-Oncology Practice · 01.02.2026 · 13 (1) · 112-125

DOI: 10.1093/nop/npaf084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 01.09.2025. Verfasst von Ytel Garcilazo-Reyes und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neuro Oncology Division, Centro Oncológico Internacional, Hospital San Angel Inn Universidad, Mexico City, Mexico. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medulloblastoma (MB) is a rare tumor in adults, with treatment strategies derived largely from pediatric data. Prognostic factors have not been uniformly defined in adults to date.

Methods

We retrospectively reviewed the medical records of 89 adult MB patients treated between 1995 and 2019 in our institution. Patient’s characteristics, disease features, and treatment modalities were analyzed for prognostic factors using univariate and multivariate analysis.

Results

Of the 89 patients, 66% were male. Most MBs were in the cerebellum (48%), with desmoplastic/nodular histology (43%), Sonic Hedgehog molecular type (79%), and M0 Chang´s stage (72%). Intermediate- and high-risk MBs were identified in ~46% and ~47% of cases, respectively. Complete/near complete tumor resection was achieved in 62% of cases. Surgery followed by chemoradiotherapy (CT/RT) was the most frequent treatment (76%) with carboplatin-based regimens used in 70% of cases. After the first-line treatment, complete response (CR) was achieved in 80% of patients. Median overall survival (mOS) was 124.4 months (95%CI 68.5-180.1) and the median progression free survival (mPFS) was 30.5 months (95%CI 13.5-47.5), the 5-year OS was 67% and the 5-year PFS was 51%. In multivariate analysis, Chang´s stage ≥ M2 metastatic classification (P = .001), RT without CT in first line setting (P = .005), and craniospinal RT < 30 Gy (P = .015) were associated with worse survival outcomes.

Conclusions

Chang’s stage ≥ M2, first-line treatment lacking CT, and first-line treatment with craniospinal RT < 30 Gy were significant predictors of poor survival. Chemoradiotherapy with craniospinal RT ≥ 30 Gy improved survival outcomes.

Schlagwörter

Stichwörter der Autor:innen

Adult medulloblastomamolecular subtypesprognostic

Autor:innen und Institutionen

  • Neuro Oncology Division, Centro Oncológico Internacional, Hospital San Angel Inn Universidad, Mexico City, Mexico.
  • Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neuro-oncologie, Paris, France.
  • Pathology Department, University hospital of Grenoble Alpes, Grenoble, France.
  • Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Department of Neuropathology, Paris, France.
  • Oncology Radiotherapy Department, Hopital Neurologique, Hospices Civils de Lyon, Bron, France.
  • Radiotherapy department, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, IHU, ICM, Paris, France.

ORCID-Profile: Ytel Garcilazo-Reyes, Franck Bielle, Franck Bourdeaut, Julien Masliah-Planchon, Ahmed Idbaih, Florence Laigle-Donadey

Zitieren

APA

Garcilazo-Reyes, Y., Dal Col, P., Bielle, F., Mokhtari, K., Feuvret, L., Jacob, J., Duran-Peña, A., Capelle, L., Savatovsky, J., Bourdeaut, F., Masliah-Planchon, J., Cacho-Díaz, B., Hoang-Xuan, K., Idbaih, A., & Laigle-Donadey, F. (2026). Prognostic factors in adult patients with medulloblastoma. Neuro-Oncology Practice, 13(1), 112-125. https://doi.org/10.1093/nop/npaf084

Vancouver

Garcilazo-Reyes Y, Dal Col P, Bielle F, Mokhtari K, Feuvret L, Jacob J, et al. Prognostic factors in adult patients with medulloblastoma. Neuro-Oncology Practice. 2026;13(1):112-125. doi:10.1093/nop/npaf084

BibTeX
@article{GarcilazoReyes2026,
  author = {Garcilazo-Reyes, Ytel and Dal Col, Pierre and Bielle, Franck and Mokhtari, Karima and Feuvret, Loïc and Jacob, Julian and Duran-Peña, Alberto and Capelle, Laurent and Savatovsky, Julien and Bourdeaut, Franck and Masliah-Planchon, Julien and Cacho-Díaz, Bernardo and Hoang-Xuan, Khê and Idbaih, Ahmed and Laigle-Donadey, Florence},
  title = {Prognostic factors in adult patients with medulloblastoma},
  journal = {Neuro-Oncology Practice},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {112--125},
  doi = {10.1093/nop/npaf084}
}
Kostenlos starten →